https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-03-01 / Eur. Urol. 2007 Mar;51(3):853-42007-03-01 00:00:002019-02-15 09:24:09Re: Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase 1 clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-01-01 / Drugs Aging 2007;24(3):197-221
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-01-01 / Drugs Aging 2007;24(3):197-2212007-01-01 00:00:002019-02-15 09:24:11Advances in prostate cancer immunotherapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-11-15 / Int. J. Cancer 2006 Nov;119(10):2428-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-11-15 / Int. J. Cancer 2006 Nov;119(10):2428-342006-11-15 00:00:002019-02-15 09:24:12Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-10-10 / Cancer Immunol. Immunother. 2007 Apr;56(4):429-45
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-10-10 / Cancer Immunol. Immunother. 2007 Apr;56(4):429-452006-10-10 00:00:002019-02-15 09:24:12Vaccination therapy in prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):434-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):434-412006-09-01 00:00:002019-02-15 09:24:13Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):413-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-09-01 / Urol. Oncol. 2006 Sep-Oct;24(5):413-82006-09-01 00:00:002019-02-15 09:24:14Basic overview of current immunotherapy approaches in urologic malignancy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-08-01 / Hematol. Oncol. Clin. North Am. 2006 Aug;20(4):965-83, xi
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-08-01 / Hematol. Oncol. Clin. North Am. 2006 Aug;20(4):965-83, xi2006-08-01 00:00:002019-02-15 09:24:15Immunotherapy for prostate cancer: what’s the future?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-06-01 / Prostate 2006 Jun;66(8):811-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-06-01 / Prostate 2006 Jun;66(8):811-212006-06-01 00:00:002019-02-15 09:24:16Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-04-13 / Cancer Immunol. Immunother. 2006 Dec;55(12):1524-33
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-04-13 / Cancer Immunol. Immunother. 2006 Dec;55(12):1524-332006-04-13 00:00:002019-02-15 08:53:03Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-04-13 / Cancer Immunol. Immunother. 2006 Nov;55(11):1432-42
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-04-13 / Cancer Immunol. Immunother. 2006 Nov;55(11):1432-422006-04-13 00:00:002019-02-15 09:24:15Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
